• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NeuroRx completes merger with SPAC, starts trading on Nasdaq

May 25, 2021 By Sean Whooley

NRx NeuroRx_LogoNeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp.

The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a news release.

Radnor, Pa.-based NRx develops Zyesami, a synthetic form of a naturally occurring peptide — vasoactive intestinal peptide (VIP) — found in the lung and known to protect the Alveolar Type II cell targeted by SARS-CoV-2, the virus causing COVID-19. The company entered a feasibility agreement with TFF Pharmaceuticals to formulate Zyesami into a dry powder to treat COVID-19 in March. The company said it plans to seek FDA emergency use authorization for Zyesami this month.

Along with Zyesami, NRx plans to use the capital collected from going public to develop its NRX-101 drug therapy combination of D-cycloserine and lurasidone for bipolar depression. Both therapeutics in development are in FDA-approved Phase 3 clinical trials right now.

NRx committed more than $120 million in operating capital from cash on hand, private investment in public equity (PIPE), warrants exercised by the global emerging markets (GEM) global yield fund and a share subscription facility provided by GEM.

Dr. Jonathan Javitt will take the reins of NRx as CEO and chairman of the board, while directors on the board include former U.S. Dept. of Health and Human Services assistant secretary Dr. Sherry Glied, former Teva Pharmaceuticals president and director Chairm Hurvitz and former chief counsel to the FDA Daniel Troy.

“Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of “Bringing Hope to Life,” said Javitt said in the release. “We are indebted to the leaders and shareholders of BRPA who have chosen to support our mission.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: NeuroRx, NRx

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS